医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

From Phase

PDCline Pharma Presents First Clinical Results From Phase I/II trial With PDClung01 at ESMO 2022

その他ヘルスバイオテクノロジーヘルスケア幹細胞感染症腫瘍学臨床試験　 TimeLine: From Phase II trial With PDC*line Pharma Presents First Clinical Results PDC*lung01 at ESMO

2022年09月13日

BeiGene Presents Updated Results from Phase 3 RATIONALE-309 Trial of PD-1 Inhibitor Tislelizumab in First-Line RM-NPC in Virtual ASCO Plenary Series

BeiGene Presents Updated Results from Phase 3 RATIONALE-309 Trial of PD-1 Inhibitor Tislelizumab in First-Line RM-NPC in Virtual ASCO Plenary Series

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: BeiGene Presents Updated Results From Phase Inhibitor Tislelizumab in First-Line RM-NPC in Virtual ASCO Plenary Series RATIONALE-309 Trial of PD

2022年04月19日

BeiGene Presents Results from Phase 3 Trial of Tislelizumab in Nasopharyngeal Cancer at ESMO Immuno-Oncology Congress 2021

BeiGene Presents Results from Phase 3 Trial of Tislelizumab in Nasopharyngeal Cancer at ESMO Immuno-Oncology Congress 2021

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: BeiGene Presents Results From Phase Trial of Tislelizumab in Nasopharyngeal Cancer at ESMO Immuno-Oncology Congress 2021

2021年12月10日

AriBio Co., Ltd. Announces Topline Results from Phase 2 Study of AR1001 in Mild to Moderate Alzheimer’s Patients

AriBio Co., Ltd. Announces Topline Results from Phase 2 Study of AR1001 in Mild to Moderate Alzheimer’s Patients

その他ヘルスバイオテクノロジーヘルスケアヘルス一般臨床試験製薬　 TimeLine: Announces Topline Results AriBio Co From Phase Study of AR1001 in Mild to Moderate Alzheimer’s Patients

2021年11月04日

Kyowa Kirin and Amgen Present Positive Late-Breaking Data from Phase 2 Study of KHK4083/AMG 451 in Adult Patients with Moderate-to-Severe Atopic Dermatitis at EADV Congress

Kyowa Kirin and Amgen Present Positive Late-Breaking Data from Phase 2 Study of KHK4083/AMG 451 in Adult Patients with Moderate-to-Severe Atopic Dermatitis at EADV Congress

バイオテクノロジーヘルスケア臨床試験製薬　 TimeLine: AMG 451 in Adult Patients with Moderate-to-Severe Atopic Dermatitis at EADV Congress From Phase Kyowa Kirin and Amgen Present Positive Late-Breaking Data Study of KHK4083

2021年10月02日

AnHeart and Innovent Announce Interim Data from Phase Ⅱ Trial (TRUST) of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting

AnHeart and Innovent Announce Interim Data from Phase Ⅱ Trial (TRUST) of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting

その他ヘルスバイオテクノロジーヘルスケア腫瘍学臨床試験製薬遺伝学　 TimeLine: AnHeart and Innovent Announce Interim Data From Phase of Taletrectinib in ROS1-Positive Trial TRUST

2021年09月27日

Affinivax and Astellas Present Safety and Immunogenicity Data from Phase 2 Study of ASP3772, a Novel 24 valent MAPS™ Vaccine for Streptococcus pneumoniae

Affinivax and Astellas Present Safety and Immunogenicity Data from Phase 2 Study of ASP3772, a Novel 24 valent MAPS™ Vaccine for Streptococcus pneumoniae

バイオテクノロジーヘルスケアヘルス一般医療用品感染症臨床試験製薬遺伝学　 TimeLine: a Novel Affinivax and Astellas Present Safety and Immunogenicity Data From Phase Vaccine for Streptococcus pneumoniae valent MAPS

2021年07月13日

BeiGene Announces Positive Topline Results from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

BeiGene Announces Positive Topline Results from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: BeiGene Announces Positive Topline Results From Phase Trial of Tislelizumab in Combination with Chemotherapy as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

2021年05月21日